Percheron Therapeutics (ASX:PER) Ending Cash Position : A$17.19 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Percheron Therapeutics Ending Cash Position?

Percheron Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was A$17.19 Mil.

Percheron Therapeutics's quarterly Ending Cash Position declined from Dec. 2022 (A$16.62 Mil) to Jun. 2023 (A$10.97 Mil) but then increased from Jun. 2023 (A$10.97 Mil) to Dec. 2023 (A$17.19 Mil).

Percheron Therapeutics's annual Ending Cash Position increased from Jun. 2021 (A$6.02 Mil) to Jun. 2022 (A$19.23 Mil) but then declined from Jun. 2022 (A$19.23 Mil) to Jun. 2023 (A$10.97 Mil).

Percheron Therapeutics Ending Cash Position Historical Data

The historical data trend for Percheron Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Percheron Therapeutics Ending Cash Position Chart

Percheron Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Ending Cash Position

Get a 7-Day Free Trial

2.90

4.06

6.02

19.23

10.97

Percheron Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															23.48	19.23	16.62	10.97	17.19

Percheron Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Percheron Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	19.232	+	-8.265
	=	10.97

Percheron Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	10.968	+	6.225
	=	17.19

Percheron Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Percheron Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Percheron Therapeutics (ASX:PER) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Percheron Therapeutics Ltd (ASX:PER) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

ATHJF:USA AWY0:Germany

Address

14 Wallace Avenue, Toorak, VIC, AUS, 3142

Website

https://www.antisense.com.au

Antisense Therapeutics Ltd is a drug manufacturer. The company is engaged in research and development of novel antisense pharmaceuticals. The company operates in two segments that have been identified based on its antisense oligonucleotide products as ATL1102 and ATL1103.

Percheron Therapeutics (ASX:PER) Headlines

No Headlines